Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer

Oncol Rep. 2001 Jan-Feb;8(1):27-31.

Abstract

We performed a dose-escalation study of carboplatin combined with a fixed dose of intraperitoneal cisplatin and G-CSF in patients with epithelial ovarian cancer, and analyzed the progression-free and overall survival. Six of the patients who entered the study with stage IC and II disease are still alive with no evidence of disease. The five-year survival rate was 61% for the 18 patients with stage III and IV disease; progression-free survival over 5 years was 32%. Our results show this to be an effective treatment regimen for epithelial ovarian cancer. Prognosis is good with this combined carboplatin/cisplatin/G-CSF therapy, especially for those patients with microscopic or no residual disease.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma, Clear Cell / drug therapy
  • Adenocarcinoma, Clear Cell / mortality
  • Adenocarcinoma, Clear Cell / pathology
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Carcinoma, Endometrioid / drug therapy
  • Carcinoma, Endometrioid / mortality
  • Carcinoma, Endometrioid / pathology
  • Child, Preschool
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cystadenocarcinoma, Mucinous / drug therapy
  • Cystadenocarcinoma, Mucinous / mortality
  • Cystadenocarcinoma, Mucinous / pathology
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / mortality
  • Cystadenocarcinoma, Serous / pathology
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematologic Diseases / chemically induced
  • Hematologic Diseases / drug therapy
  • Hematologic Diseases / prevention & control
  • Humans
  • Infusions, Intravenous
  • Injections, Intraperitoneal
  • Japan / epidemiology
  • Life Tables
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / pathology
  • Prognosis
  • Survival Analysis
  • Treatment Outcome

Substances

  • Granulocyte Colony-Stimulating Factor
  • Carboplatin
  • Cisplatin